Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.48−0.03 (-5.42%)
Close on Nov 17, 2026Market cap $73.93MP/E –Yield –
Coherus Oncology price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Coherus Oncology's price to book ratio was 1.5× on Nov 11, 2026, against 1.8× a year earlier. Over the last 5 years it ranged from 1.1× to 68.0×, with a median of 7.8×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.5× | −0.4 |
| 2025 | Dec 31, 2025 | 1.9× | −50.3 |
| 2022 | Jul 29, 2022 | 52.1× | +42.8 |
| 2021 | Dec 31, 2021 | 9.3× | +3.8 |
| 2020 | Dec 31, 2020 | 5.5× | −62.4 |
| 2019 | Jan 31, 2019 | 68.0× | +22.3 |
| 2018 | Dec 31, 2018 | 45.7× | +37.9 |
| 2017 | Dec 29, 2017 | 7.8× | −28.7 |
| 2016 | Dec 30, 2016 | 36.5× | +17.6 |
| 2015 | Dec 31, 2015 | 18.8× | – |
See a number that looks wrong?